INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
INmuneBIO has raised $19.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2025.
INmuneBIO's investors include Silicon Valley Bank, Alector, Toucan Capital.
INmuneBIO is headquartered in La Jolla, United States.
INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
INmuneBIO is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"INmuneBIO — Funding & Investors." VCBacked, June 27, 2025, https://www.vcbacked.co/company/inmunebio. Accessed September 30, 2026.
VCBacked. (2025). INmuneBIO — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/inmunebio
{{cite web |title=INmuneBIO — Funding & Investors |url=https://www.vcbacked.co/company/inmunebio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated